Enterprise Value
8.39B
Cash
3.423B
Avg Qtr Burn
N/A
Short % of Float
4.31%
Insider Ownership
1.43%
Institutional Own.
99.44%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details Solid tumor/s, Cancer, Metastatic merkel cell carcinoma, Skin cancer | Approved Quarterly sales | |
Pemazyre® (pemigatinib) Details 8p11 myeloproliferative syndrome | Approved Quarterly sales | |
QD Ruxolitinib XR Details Myelofibrosis | NDA FDA meeting | |
Opzelura™ (ruxolitinib) cream Details Atopic dermatitis | Phase 3 Data readout | |
Phase 3 Data readout | ||
Povorcitinib (JAK1) Details Vitiligo | Phase 3 Initiation | |
Povorcitinib (JAK1) Details Prurigo nodularis | Phase 3 Initiation | |
Povorcitinib (JAK1) Details Hidradenitis suppurativa | Phase 2 Data readout | |
INCB57643 (BETi)+ruxolitinib Details Myelofibrosis | Phase 2 Data readout | |
INCB99280/INCB99318 PD-L1 (oral) Details Solid tumor/s | Phase 2 Data readout | |
ALK2 + ruxolitinib Details Myelofibrosis | Phase 2 Data readout | |
Axatilimab Details Graft-versus-host disease | Phase 2 Data readout | |
INCA033989 (mCALR) Details Myelofibrosis | Phase 1 Data readout | |
Parsaclisib + ruxolitinib Details Myelofibrosis | Failed Discontinued |